<![CDATA[Terns Pharmaceuticals Inc. 보도자료 - 뉴스와이어]]>https://www.newswire.co.kr/?md=A10&act=article&no=31886>Fri, 01 May 2026 20:02:12 +0900Copyright (c) 2004~2026 Korea Newswire All rights reservedko-KR<![CDATA[Terns Pharmaceuticals to Present Data on Multiple NASH Programs at The Digital International Liver Congress™ 2020]]>https://www.newswire.co.kr/newsRead.php?no=909568Fri, 21 Aug 2020 14:30:00 +0900<![CDATA[턴스 파마슈티컬스, 디지털 국제 간 학술대회 2020서 다수의 NASH 프로그램에 관한 데이터 발표]]>https://www.newswire.co.kr/newsRead.php?no=909569Fri, 21 Aug 2020 14:30:00 +0900<![CDATA[Terns Pharmaceuticals Appoints Senthil Sundaram as Chief Executive Officer, Mark Vignola, Ph.D., as Chief Financial Officer, and Erin Quirk, M.D., as President]]>https://www.newswire.co.kr/newsRead.php?no=909082Tue, 11 Aug 2020 14:00:00 +0900<![CDATA[턴스 파마슈티컬스, 센틸 순다람을 최고경영자, 마크 비뇰라 박사를 최고재무책임자, 에린 쿼크 박사를 사장으로 임명]]>https://www.newswire.co.kr/newsRead.php?no=909083Tue, 11 Aug 2020 14:00:00 +0900<![CDATA[Terns Pharmaceuticals Announces Completion and Positive Results from Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH]]>https://www.newswire.co.kr/newsRead.php?no=908648Fri, 31 Jul 2020 11:30:00 +0900<![CDATA[턴스 파마슈티컬스, 비알코올성 지방간염(NASH) 치료 위해 개발 중인 SSAO 억제제 TERN-201의 임상 제1상 시험 완료 및 긍정적 결과 발표]]>https://www.newswire.co.kr/newsRead.php?no=908649Fri, 31 Jul 2020 11:30:00 +0900<![CDATA[Terns Pharmaceuticals and Hansoh Pharma Announce Collaboration and License Agreement for TRN-000632 in Greater China]]>https://www.newswire.co.kr/newsRead.php?no=908514Wed, 29 Jul 2020 11:40:00 +0900<![CDATA[턴스 파마슈티컬스, 한소 파마와 중화권 내 TRN-000632 개발 협력 및 라이선스 계약 체결]]>https://www.newswire.co.kr/newsRead.php?no=908515Wed, 29 Jul 2020 11:40:00 +0900<![CDATA[Terns Pharmaceuticals Announces Initiation of Patient Dosing in the LIFT Study, a Phase 2a Clinical Trial of TERN-101 in Development for NASH]]>https://www.newswire.co.kr/newsRead.php?no=908270Thu, 23 Jul 2020 11:50:00 +0900<![CDATA[턴스 파마슈티컬스, NASH 치료 위해 개발 중인 TERN-101의 제2a상 LIFT 임상시험서 환자 투약 개시 발표]]>https://www.newswire.co.kr/newsRead.php?no=908271Thu, 23 Jul 2020 11:50:00 +0900<![CDATA[Terns Pharmaceuticals Initiates the LIFT Study, a Phase 2a Clinical Trial of TERN-101 for the Treatment of NASH]]>https://www.newswire.co.kr/newsRead.php?no=906651Fri, 19 Jun 2020 16:30:00 +0900<![CDATA[턴스 파마슈티컬스, NASH 치료용 TERN-101의 전기 제2상 임상시험 개시]]>https://www.newswire.co.kr/newsRead.php?no=906652Fri, 19 Jun 2020 16:30:00 +0900<![CDATA[턴스 파마슈티컬스, NASH 치료 위해 개발 중인 SSAO억제제 TERN-201에 대한 1상 임상시험 데이터 발표]]>https://www.newswire.co.kr/newsRead.php?no=902190Fri, 06 Mar 2020 17:12:29 +0900<![CDATA[Terns Pharmaceuticals to Present Data from an Ongoing Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH]]>https://www.newswire.co.kr/newsRead.php?no=902188Fri, 06 Mar 2020 17:11:03 +0900<![CDATA[턴스 파마슈티컬스, NASH 치료제 개발을 위한 간 선택적 FXR 작용제인 TERN-101의 1상 임상시험의 안전성 및 약력학적 결과 발표]]>https://www.newswire.co.kr/newsRead.php?no=901519Thu, 20 Feb 2020 11:03:41 +0900<![CDATA[Terns Pharmaceuticals Announces Safety and Pharmacodynamic Results of a Phase 1 Clinical Trial of TERN-101, a Liver-Selective FXR Agonist in Development for the Treatment of NASH]]>https://www.newswire.co.kr/newsRead.php?no=901518Thu, 20 Feb 2020 10:55:51 +0900<![CDATA[턴스 파마슈티컬스, 비알코올성 지방간염 치료제로 개발 중인 SSAO 억제제 TERN-201 임상 1상 중간 결과 발표]]>https://www.newswire.co.kr/newsRead.php?no=899935Mon, 13 Jan 2020 09:39:50 +0900<![CDATA[Terns Pharmaceuticals Presents Results From An Ongoing Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH]]>https://www.newswire.co.kr/newsRead.php?no=899933Mon, 13 Jan 2020 09:35:27 +0900<![CDATA[미국 FDA, 턴스 파마슈티컬스의 FXR 작용제인 TERN-101을 NASH 치료 위한 신속심사 대상으로 지정]]>https://www.newswire.co.kr/newsRead.php?no=896412Wed, 30 Oct 2019 13:47:12 +0900<![CDATA[Terns Pharmaceuticals Receives Fast Track Designation From the FDA for TERN-101, an FXR Agonist for the Treatment of NASH]]>https://www.newswire.co.kr/newsRead.php?no=896411Wed, 30 Oct 2019 13:41:26 +0900<![CDATA[턴스 파마슈티컬, FXR 작용제 TERN-101의 긍정적 전임상 시험 데이터를 2019 간 학술회의서 발표]]>https://www.newswire.co.kr/newsRead.php?no=895638Wed, 16 Oct 2019 13:41:57 +0900<![CDATA[Terns Pharmaceuticals to Present Positive Preclinical Data on FXR Agonist TERN-101 at The Liver Meeting® 2019]]>https://www.newswire.co.kr/newsRead.php?no=895637Wed, 16 Oct 2019 13:33:15 +0900<![CDATA[턴스 파마슈티컬, NASH 치료 위한 SSAO 억제제 TERN-201에 대한 1상 임상시험 중간결과 발표]]>https://www.newswire.co.kr/newsRead.php?no=892591Wed, 14 Aug 2019 11:54:35 +0900<![CDATA[Terns Pharmaceuticals Announces Positive Interim Results From Ongoing Phase 1 Clinical Trial of TERN-201, a SSAO Inhibitor in Development for NASH]]>https://www.newswire.co.kr/newsRead.php?no=892590Wed, 14 Aug 2019 11:45:10 +0900<![CDATA[턴스 파마슈티컬스, 최고재무책임자에 안강 리 의학박사·법학박사·공인재무애널리스트 임명]]>https://www.newswire.co.kr/newsRead.php?no=890646Tue, 02 Jul 2019 13:54:48 +0900